The α7 subunit-containing nicotinic acetylcholine receptor (α7nAChR) is an essential component in the vagus nerve-based cholinergic anti-inflammatory pathway that regulates the levels of TNF, high mobility group box 1 (HMGB1), and other cytokines during inflammation. Choline is an essential nutrient, a cell membrane constituent, a precursor in the biosynthesis of acetylcholine, and a selective natural α7nAChR agonist. Here, we studied the anti-inflammatory potential of choline in murine endotoxemia and sepsis, and the role of the α7nAChR in mediating the suppressive effect of choline on TNF release. Choline (0.1-50 mM) dosedependently suppressed TNF release from endotoxin-activated RAW macrophage-like cells, and this effect was associated with significant inhibition of NF-κB activation. Choline (50 mg/kg, intraperitoneally [i.p.]) treatment prior to endotoxin administration in mice significantly reduced systemic TNF levels. In contrast to its TNF suppressive effect in wild type mice, choline (50 mg/kg, i.p.) failed to inhibit systemic TNF levels in α7nAChR knockout mice during endotoxemia. Choline also failed to suppress TNF release from endotoxin-activated peritoneal macrophages isolated from α7nAChR knockout mice. Choline treatment prior to endotoxin resulted in a significantly improved survival rate as compared with saline-treated endotoxemic controls. Choline also suppressed HMGB1 release in vitro and in vivo, and choline treatment initiated 24 h after cecal ligation and puncture (CLP)-induced polymicrobial sepsis significantly improved survival in mice. In addition, choline suppressed TNF release from endotoxin-activated human whole blood and macrophages. Collectively, these data characterize the anti-inflammatory efficacy of choline and demonstrate that the modulation of TNF release by choline requires α7nAChR-mediated signaling.
INTRODUCTION
The excessive production of the proinflammatory cytokines TNF, high mobility group box 1 (HMGB1), and other inflammatory molecules by immune cells and their subsequent release into the circulation are associated with unrestrained inflammation: a hallmark of septic shock, sepsis, and other disorders (1, 2) . Exacerbated release of TNF and other proinflammatory cytokines, and lethality during endotoxemia and sepsis, can be controlled by the efferent vagus nervebased cholinergic anti-inflammatory pathway (3) (4) (5) (6) (7) . Recent research has demonstrated that the α7 subunitcontaining nicotinic acetylcholine receptor (α7nAChR) is an important component of the mechanism underlying the anti-inflammatory efficacy of the cholinergic anti-inflammatory pathway (4, 8) . Activation of this pathway by stimulation of the vagus nerve suppresses serum TNF levels in endotoxemic animals (3, 4) , but fails to cause statistically significant effects in mice lacking the α7nAChR (4). Accordingly, α7nAChR agonists, including GTS-21, reduce systemic proinflammatory cytokine levels during murine endotoxemia, sepsis (9) , and other inflammatory conditions (10, 11) , and improve survival (9) .
Choline is a selective and endogenous α7nAChR agonist (12) (13) (14) . Choline also has other important physiological functions; this essential nutrient is a major donor of methyl groups, a cell membrane constituent, and a precursor in the biosynthesis of the neurotransmitter acetylcholine (15) (16) (17) . Although previous studies have shown protective effects of choline against endotoxin-induced shock and organ damage (18) (19) (20) , the mechanism of the anti-inflammatory action of
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William R Parrish, 1 Mauricio Rosas-Ballina, 1 Margot Gallowitsch-Puerta, 1 Mahendar Ochani, this compound is not well understood. A particularly important question is whether the α7nAChR, which is an essential component of the cholinergic antiinflammatory pathway, mediates the anti-inflammatory action of choline during endotoxemia. Another relevant question is whether choline suppresses the pro-inflammatory cytokine response and affects the survival rate during polymicrobial sepsis.
In this study, we provide evidence that choline functions as an anti-inflammatory molecule through an α7nAChR-dependent mechanism. In contrast to its anti-inflammatory effect in wild type mice, choline failed to reduce endotoxininduced serum TNF levels in α7nAChR KO mice and TNF release from peritoneal macrophages isolated from these mice. These findings represent the first direct experimental evidence that the anti-inflammatory activity of a cholinergic agonist is mediated in vivo through an α7nAChR-dependent mechanism. We also show that choline suppresses the release of HMGB1, and choline treatment initiated within a clinically relevant time frame significantly improves survival in mice with severe sepsis.
MATERIALS AND METHODS
Animals
Male mice (BALB/c at 25-28 g [Taconic] , and wild type [WT] or α7nAChR knockout [KO] C57BL/6 at 8-12 wk old) were used for in vivo studies, and WT or α7nAChR KO C57BL/ 6 female mice at 8-12 wk old were used in ex vivo peritoneal macrophage studies. All C57BL/6 animals were bred on site from heterozygous α7nAChR KO animals obtained from Jackson Laboratories (Bar Harbor, ME, USA). The genotype of the α7nAChR locus (CHRNA7) of all progeny was determined by genomic PCR using the Extract and Amp kit (Sigma, St. Louis, MO, USA). Animals were housed in standard conditions (room temperature 22°C with a 12-h light:dark cycle) with free access to regular chow and water. Animals were allowed to acclimate for at least 14 Nuclear Protein Extraction for NF-κB Activity Determination and Electrophoretic Mobility-Shift Assay (EMSA) RAW 264.7 macrophages were treated with the indicated concentrations of choline followed by LPS (4 ng/mL). Two h after LPS stimulation, cells were processed for nuclear protein extraction as described previously (9) . EMSA was performed using the Nushift NF-κB p65 kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions, as described previously (9) .
Endotoxemia and Drug Treatment
Endotoxemia was induced by injecting mice intraperitoneally (i.p.) with 6 mg/kg endotoxin, which caused ~80% mortality. Mice were treated i.p. with the indicated dose of choline or vehicle (sterile saline) at 6 h, and at 30 min prior to endotoxin administration. Animals were euthanized by CO 2 asphyxiation 1.5 h after endotoxin injection, and blood was collected by cardiac puncture. Blood was centrifuged at 1,500g for 15 min to isolate serum. Sera were used for TNF analysis by ELISA (R&D Systems) according to the manufacturer's recommendations. In survival experiments, mice were treated i.p. with choline (50 mg/kg or 5 mg/kg) or sterile saline (controls) at 6 h and at 30 min prior to endotoxin injection. Survival was monitored for 2 wks.
Isolation and Treatment of Mouse Peritoneal Macrophages
WT or α7nAchR KO C57BL/6J female mice were injected with 2 mL of 9% thioglycollate broth i.p. to elicit peritoneal macrophages. Animals were euthanized by CO 2 asphyxiation 42-48 h later, and cells were collected by lavage of the peritoneal cavity three times with 5 mL ice-cold 11.6% sucrose. Cells were washed three times with phosphatebuffered saline (PBS) and once with RPMI 1640 medium and resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM glutamine (Biowhittaker) and 100U/mL Penicillin, 100 μg/mL Streptomycin (Gibco). Cells were seeded at 1.5 × 10 6 per well into 24-well Falcon Primaria tissue culture dishes and were allowed to adhere for 2 h at 37°C under 5% CO 2 . Then, cells were washed twice with PBS and supplied with fresh medium as described above, returned to the incubator, and allowed to rest for 18-24 h. Prior to treatment, media were removed and replaced with serum free Optimem media. Cells were incubated with the indicated concentration of choline for 10 min prior to LPS (100 ng/mL) exposure. Cell culture media were harvested 4 h after LPS treatment and TNF was assayed by ELISA (R&D Systems) according to the manufacturer's recommendations.
Cecal Ligation and Puncture Surgery and Drug Treatment
Severe polymicrobial sepsis was induced by cecal ligation and puncture (CLP). Mice were anesthetized using ketamine (100 mg/kg) and xylazine (8 mg/kg) administered intramuscularly. Abdominal access was gained via a midline incision. The cecum was isolated and ligated with a 6-0 silk ligature below the ileocecal valve and then punctured once with a 22 G needle. Stool (approximately 1 mm) was extruded from the hole, and the cecum placed back into the abdominal cavity. The abdomen was closed with two layers of 6-0 Ethilon sutures. An antibiotic (Imipenem-Cilastatin, 0.5 mg/kg, subcutaneously, in a total volume of 0.5 mL/mouse) was administered immediately after CLP as part of the resuscitation fluid. Sham-operated animals had the cecum isolated and then returned to the peritoneal cavity without being ligated or punctured. Sham animals also received an antibiotic treatment and resuscitative fluid as described above. For HMGB1 determination, mice were randomized 24 h after CLP and were injected i.p. with either sterile saline or choline (25 mg/kg). Mice received additional treatments at 30 h and 44 h after CLP. Blood was collected by cardiac puncture at 45 h after CLP, and serum HMGB1 levels were determined by quantitative Western blot analysis as described above. For survival studies, 24 h after CLP, mice were randomized and injected i.p. with either sterile saline or choline (25 mg/kg or 5 mg/kg). This treatment was repeated 6 h later (30 h after CLP) and then twice daily for 2 d for a total of six treatments. Survival was routinely monitored for 2 wks.
Isolation and Treatment of Human Macrophages
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient fractionation from whole blood that was obtained from anonymous donors through the Long Island Blood Services (Westbury, NY, USA), and were differentiated to macrophages in culture as described previously (4) . Briefly, PBMCs were harvested from the plasma/FicolHypaque interface after centrifugation for 30 min at 550g. Cells were washed twice with PBS, once with RPMI 1640 medium, and resuspended in RPMI 1640 supplemented with 10% heat-inactivated human serum, 2 mM glutamine (Biowhittaker), and 100U/mL Penicillin, 100 μg/mL Streptomycin (Gibco). Cells were then seeded at 5 × 10 7 per 10 cm Cells were washed once and resuspended in medium supplemented with human recombinant macrophage colonystimulating factor (hrMCSF), and were seeded into 24-well Falcon Primaria tissue culture plates at 1 × 10 6 cells per well. Cultures were incubated for 6 d in the presence of hrMCSF to promote macrophage differentiation. Macrophages were rested for 24 h in the absence of hrMCSF prior to use. Media were removed and replaced with serum free Optimem media prior to treatment. Cells were incubated with the indicated concentration of choline for 10 min prior to exposure to LPS (20 ng/mL). Cell culture media were harvested 4 h after LPS treatment and secreted TNF was assayed by ELISA (R&D Systems) as described above.
Statistical Analysis
Data are expressed as mean ± SEM. Significant differences were assessed by using one way analysis of variance (ANOVA) followed by a Student t test. The statistical significance of differences between groups of animals in survival experiments was analyzed by the logrank test. Differences with P < 0.05 were considered statistically significant.
RESULTS
Choline Inhibits Endotoxin-Induced TNF Release and NF-κB Activation
The anti-inflammatory efficacy of cholinergic agonists has been tested previously by using RAW-264.7 mouse macrophage-like cells (9), a wellestablished cell culture system for in vitro studies of innate immune cell inflammatory responses. We studied the efficiency of choline in inhibiting TNF release from endotoxin-activated RAW cells. The cells were pre-incubated for 10 min with increasing choline concentrations prior to endotoxin activation. As shown in Figure 1A , choline dose-dependently suppressed endotoxin-stimulated TNF release from RAW cells. NF-κB is a key transcription factor that is activated in response to endotoxin for the production of inflammatory mediators such as TNF. Therefore, we tested whether the choline-induced suppression of TNF was associated with inhibition of NF-κB activation. RAW cells were incubated for 10 min in the absence or presence of increasing concentrations of choline prior to exposure to endotoxin. Nuclear extracts were prepared and electrophoretic mobility shift assays (EMSA) were conducted to measure activated NF-κB. Choline dose-dependently suppressed NF-κB activation in response to endotoxin ( Figure 1B) .
Choline Suppresses Systemic TNF Levels During Endotoxemia Through an α7nAChR-Mediated Mechanism
Based on our in vitro data, we next tested whether choline reduces systemic TNF during endotoxemia. Choline (5 mg/kg or 50 mg/kg) or vehicle (saline) was injected into BALB/c mice at 6 h and at 30 min prior to endotoxin (6 mg/kg i.p.) administration. This dose of endotoxin previously was shown to cause about 80% mortality (9) . The higher choline dose (50 mg/kg) significantly suppressed serum TNF levels ( Figure 2A ). The lower choline dose (5 mg/kg) failed to alter serum TNF levels (see Figure 2A) . In light of the recently discovered role for the α7nAChR in mediating the cholinergic suppression of systemic TNF during endotoxemia (4), and the fact that choline is a selective α7nAChR agonist, we tested the efficacy of choline in suppressing systemic TNF levels during endotoxemia in WT and α7nAChR KO mice. WT and agematched α7nAChR KO mice were injected i.p. with choline (50 mg/kg) or vehicle (saline) at 6 h and at 30 min prior to endotoxin (6 mg/kg, i.p.) administration. Choline significantly suppressed systemic TNF levels in endotoxemic WT mice as compared with saline-treated endotoxemic controls ( Figure 2B , P < 0.05). In contrast, choline administration in α7nAChR KO mice did not alter systemic TNF levels significantly, as compared with controls (see Figure 2B ). Macrophages represent a major source of TNF during endotoxemia (21, 22) , and the α7nAChR expressed on macrophages plays a critical role in mediating cholinergic anti-inflammatory signaling (4). Therefore, we reasoned that choline may suppress macrophage TNF release through an α7nAChR-dependent signaling mechanism. Accordingly, we examined the effect of choline on TNF release from endotoxin-activated peritoneal macrophages collected from WT mice and α7nAChR KO mice. Peritoneal macrophages were exposed to the indicated concentrations of choline 10 min prior to the addition of endotoxin, and TNF levels were measured in media supernatants collected 4 h later. As shown in Figure 2C , choline dose-dependently suppressed TNF release by macrophages from WT mice. However, choline treatment did not suppress TNF release by macrophages isolated from α7nAChR KO mice (see Figure 2C ).
Choline Improves Survival in Lethal Endotoxemia
We have shown previously that the α7nAChR agonist GTS-21 significantly improves survival of BALB/c mice during endotoxemia (9) . We next studied whether choline improves survival in lethal endotoxemia. Choline (5 mg/kg or 50 mg/kg, i.p.) or vehicle (saline, i.p.) was injected into BALB/c mice at 6 h and at 30 min prior to the i.p. administration of endotoxin (6 mg/kg, i.p.). Vehicle-treated mice showed a 27% survival rate that was not improved by 5 mg/kg choline ( Figure 3) . In contrast, treatment with 50 mg/kg choline resulted in a significantly improved survival rate of 63% (see Figure 3) .
Choline Suppresses HMGB1 Release and Improves Survival in Mice with Severe Sepsis
HMGB1 is a late pro-inflammatory cytokine mediator of inflammation during experimental sepsis and an important therapeutic target in the treatment of this disorder (23) (24) (25) . We studied whether choline suppresses HMGB1 release in Figure 1 . Choline inhibits TNF release (A) and NF-κB activation (B) in endotoxinstimulated RAW-264.7 mouse macrophagelike cells. (A) RAW cells were exposed to the indicated concentration of choline 10 min prior to the addition of endotoxin (4 ng/mL). Culture supernatants were harvested 4 h later and TNF was determined by ELISA. Data represent the mean ± SEM of two representative experiments conducted in duplicate (*P < 0.04 as compared, with vehicle [V] treated controls). (B) RAW cells were exposed to the indicated concentrations of choline 10 min prior to the addition of endotoxin (4 ng/mL) and cells were harvested 2 h after endotoxin challenge for determination of NF-κB activation by EMSA. Autoradiographs were subjected to densitometry by using Quantity One software (Biorad). Data represent the mean ± SEM of three independent experiments (*P < 0.04, **P < 0.006 as compared with the lowest choline concentration tested).
vitro and in vivo and improves survival of mice with polymicrobial sepsis. Based on our data that choline suppresses TNF release and NF-κB activation in RAW cells (see Figure 1A ,1B), we tested whether choline also attenuates HMGB1 release from RAW cells. Choline dosedependently reduced HMGB1 release from endotoxin-stimulated RAW cells ( Figure 4A ). We next studied whether choline suppresses serum levels of HMGB1 in mice with CLP-induced sepsis. Choline (25 mg/kg) or saline were injected i.p. to septic mice 24 h after the CLP surgery. Mice received additional treatments 30 h and 44 h after CLP, and serum HMGB1 levels were determined in blood obtained at 45 h after CLP. Serum HMGB1 levels were reduced by 85% in the animals receiving choline as compared with the saline-administered controls ( Figure 4B ). It is noteworthy that the mortality rate at the 45-h time point was higher in saline-treated mice (5/12) compared with the choline-treated group (1/12) (data not shown). We then specifically tested whether choline improves survival when therapeutically administered to septic mice. Choline (25 mg/kg, or 5 mg/kg) or vehicle (saline) was administered i.p. to mice with CLP-induced sepsis 24 h after surgery. This treatment was repeated 6 h later (30 h after surgery) and twice daily for 2 d more. The survival rate for choline-treated (25 mg/kg) mice (64%) was improved significantly when compared with control animals (23%) ( Figure 4C ). The 42% survival rate of septic mice treated with the lower choline dose (5 mg/kg) was not significantly different as compared with control mice (see Figure 4C ). These data show that therapeutically administered choline attenuates systemic HMGB1 levels and improves survival in polymicrobial sepsis.
Choline Suppresses TNF Production from Endotoxin-Stimulated Human Whole Blood and Cultured Macrophages
To examine the anti-inflammatory efficiency of choline in human cells, we Figure 2 . Choline suppresses systemic TNF levels during endotoxemia through an α7nAChR-dependent mechanism. (A) Choline or vehicle (V, saline) was injected i.p. in BALB/c mice (n = 10 per group) at 6 h, and at 30 min, prior to endotoxin (6 mg/kg, i.p.) administration. Serum TNF was analyzed by ELISA in blood obtained 90 min after endotoxin administration. Results show the mean ± SEM for each group (*P < 0.05 as compared with vehicle (V) administered controls). (B) Choline (50 mg/kg, i.p.) or saline was injected i.p. in age-matched WT and α7nAchR KO mice (WT n = 8-9/group, α7nAChR KO n = 7-9/group) at 6 h, and at 30 min, prior to endotoxin (6 mg/kg, i.p.) administration. Serum TNF was analyzed by ELISA in blood obtained 90 min after endotoxin administration. Results show the mean ± SEM for each treatment group (*P < 0.001 as compared with saline administered controls). (C) Peritoneal macrophages from age-matched WT and α7nAChR KO mice were incubated with the indicated concentrations of choline or vehicle (V) for 10 min prior to exposure to endotoxin (100 ng/mL). TNF in cell culture media was determined by ELISA 4 h after endotoxin addition. Results represent the mean ± SEM of three independent experiments conducted in duplicate (*P < 0.04, **P < 0.02, ***P < 0.002 as compared with lowest choline concentration tested). tested whether choline suppressed TNF release from endotoxin-activated human whole blood and cultured human macrophages. Blood was collected from healthy volunteers and blood samples were exposed to increasing concentrations of choline or vehicle for 10 min prior to the addition of endotoxin. As shown in Figure 5A , choline (50 mM) significantly suppressed endotoxininduced TNF release from human whole blood. In a parallel set of experiments, human macrophages that express the α7nAChR (4) were differentiated from peripheral blood mononuclear cells (PBMCs) and treated with various choline concentrations 10 min prior to the addition of endotoxin. As shown in Figure 5B , choline (1 mM) significantly reduced TNF release from endotoxinstimulated human macrophages. The level of TNF suppression did not increase with higher concentrations of choline (up to 50mM) (data not shown). RAW cells were exposed to the indicated concentration of choline or vehicle 10 min prior to LPS (100 ng/mL) addition for 24 h. Culture supernatants were harvested, and secreted HMGB1 was detected by Western blot analysis. HMGB1 was not detected in the supernatant from cells that were not treated with LPS. Data represent the mean ± SEM of four experiments conducted in duplicate (*P < 0.05, **P < 0.02, ***P < 0.001 as compared with lowest choline concentration tested). (B) Mice (n = 12) were administered i.p. with either saline or choline (25 mg/kg) 24 h after CLP . Mice received additional treatments at 30 h and 44 h after CLP . Serum HMGB1 levels were determined in surviving mice (n = 11 for choline treatment, n = 7 for control treatment) in blood obtained at 45 h after CLP (*P < 0.0008). (C) Mice (n = 26 per group) were subjected to CLP surgery. 24 h after CLP, mice were randomized and injected i.p. with either saline or choline (25 mg/kg). This treatment was repeated 6 h later (30 h after CLP) and twice daily for 2 d more for a total of six treatments, and survival was monitored for 2 wks (*P < 0.002). 
DISCUSSION
In this study, we show that choline suppresses serum TNF levels in endotoxemic mice and this anti-inflammatory effect of choline is dependent on an α7nAChR-mediated signaling. In addition, we demonstrate the anti-inflammatory efficacy of choline in experimental polymicrobial sepsis and in human cells.
Choline suppressed systemic TNF levels in endotoxemic mice, but failed to reduce TNF levels in mice lacking the α7nAchR (α7nAchR KO mice) and these findings clearly indicate the α7nAChR dependence of this anti-inflammatory in vivo effect of choline. In contrast to its suppressive effect on TNF release from endotoxin-stimulated WT peritoneal macrophages, choline did not suppress TNF release from α7nAChR KO cells. These results strengthen the concept that α7nAChR expressed on macrophages and other immune cells plays a critical role in controlling inflammatory responses (4, 26) .
Choline, a byproduct of acetylcholine degradation, is a stable, natural, and selective agonist on α7nAChR. Earlier studies indicated that acetylcholine suppresses TNF release from peritoneal mouse macrophages and human macrophages (3, 4) , but it was unknown previously whether choline also can regulate TNF in these cells. Interestingly, our data show that choline concentrations that suppress TNF release from these endotoxin-stimulated immune cells are significantly higher than acetylcholine concentrations (in the presence of an acetylcholinesterase inhibitor) that exert similar suppressive effects (3, 4) . These observations are in line with studies showing a lower agonistic efficacy of choline on neuronal α7nAChRs as compared with acetylcholine (14, 27, 28) and have implications for signaling after acetylcholine release, because choline can persist after acetylcholine degradation.
The expression of the α7nAChR in several non-neuronal cells, including macrophages, monocytes, and dendritic cells, has been documented (8, 29, 30) . However, knowledge about the receptor function and pharmacological characteristics related to cytokine production is very limited. Previously, agonistic properties of choline have been studied on neuronal α7nAChRs and it has been shown that choline is a full agonist on the α7nAChR with an EC 50 of 1.6 mM (12) . These data were suggestive for the drug concentrations we used to study the effects of choline on TNF release, NF-κB activation, and HMGB1 release in response to endotoxin. Our results show that choline concentrations required to cause statistically significant suppression of TNF release and NF-κB activation in vitro are generally higher than those that suppress HMGB1 release. This observation may indicate that the cellular mechanisms governing the release of HMGB1 could be more sensitive to cholinestimulated α7nAChR signaling than those controlling the release of TNF. This in vitro difference also was extrapolated to the in vivo studies. While a choline dose of 50 mg/kg was required to suppress serum TNF significantly and to improve survival during endotoxemia, a lower choline dose of 25 mg/kg significantly inhibited serum HMGB1 levels and improved survival in mice with polymicrobial sepsis. A possible explanation could be related to differences between the underlying inflammatory mechanisms of endotoxemia and CLPsepsis. The survival-improving effect of choline, administered i.p. 6 h and 30 min prior to endotoxin is in line with a previous study, demonstrating that a cholinerich diet improves survival in endotoxemic rats (18) . Moreover, our results that choline treatment, initiated within a clinically relevant time frame, improves survival in polymicrobial sepsis indicate the potential for clinical development of choline.
Choline deficiency has been shown previously to induce liver injury in humans and in rodents, which is exacerbated upon endotoxin administration (31, 32) . In contrast, choline (20 mg/kg, intravenous [i.v.]) administration suppresses TNF release and attenuates inflammation during endotoxemia in dogs (19, 20) . Moreover, choline (60 mg/kg, i.v.) attenuates acid-induced lung injury in mice (33) . The effective doses of choline used in the present study (25-50 mg/kg, i.p.) are within the dose range used in these other studies. It is important to note that we did not observe any adverse neurobehavioral effects of these choline doses, which are comparable with the recommended tolerable upper limit of dietary choline intake in humans (34) . Unlike other synthetic α7nAChR agonists, choline is an endogenous molecule with important physiological functions, including its vital roles in maintaining the structural integrity of cell membranes and providing methyl groups for the synthesis of betaine, thus participating in methionine, folate, and homocysteine metabolism (34) . While some of these metabolic functions have been linked previously to antiinflammatory effects of choline (18, 35) our data clearly show that α7nAChR signaling is required for the antiinflammatory efficacy of this compound during endotoxemic shock. Our results (data not shown) also indicate that α7nAChR plays a role in mediating the anti-inflammatory efficacy of choline in polymicrobial sepsis. Therefore, our findings bring new light to these previous studies and suggest that endogenous choline may act on the α7nAChR and play an important role in regulating innate immune responses to maintain homeostasis. Choline also is a precursor for the synthesis of acetylcholine, which is the principle neurotransmitter of the efferent vagus nerve (36) . It is possible that a portion of the exogenous choline is metabolized as a substrate for acetylcholine biosynthesis, which may contribute to anti-inflammatory effects in vivo. In the cholinergic synapse, acetylcholine is degraded rapidly by acetylcholinesterases into acetate and choline. Choline generated in this mode may act to prolong α7nAChR activation selectively (36) . While indicating a critical anti-inflammatory role for choline as an α7nAChR agonist, we cannot entirely exclude the contribution of other effects of choline to its anti-inflammatory activity in vivo, including the stimulation of cholinergic signaling in the central nervous system (CNS), which has been shown recently to play a role in controlling inflammation during endotoxemia (37) . However, it is possible that these alternative pathways also culminate in α7nAChR-mediated signaling.
Choline also suppressed TNF release from endotoxin-activated human whole blood and macrophages effectively, demonstrating the anti-inflammatory efficacy of this compound in human cells. In conclusion, our data provide experimental evidence that the cholinergic agonist choline suppresses TNF release through an α7nAChR-dependent mechanism and has therapeutic potential in the treatment of sepsis and other inflammatory diseases.
